Company: KAUFMANN PHARMA INCLast updated:Audience: Licensed health professionals
Registered with the Philippine FDA as a FOOD SUPPLEMENT — no approved therapeutic claims. Not a substitute for prescribed treatment.
CKD · dialysis · transplant
Kidney notes
The Flavos food supplement is registered as Phyllanthus niruri (stonebreaker), rosemary (Rosmarinus officinalis) and basil (Ocimum basilicum). It is marketed for kidney stones and urinary health. It is a different registration from any Flavos-branded drug product.
Evidence
No clinical trials of Flavos itself were identified on PubMed.
Phyllanthus niruri: in an RCT of 69 calcium stone formers given 450 mg three times daily or placebo for 3 months, urinary parameters did not change overall; urinary calcium fell only in the hypercalciuric subgroup, and stone passage and pain did not differ (Nishiura 2004).
A meta-analysis found two controlled studies, with modest reductions in stone size and number (Dhawan 2020). A 2025 systematic review describes it as safe in the available studies and possibly helpful after shock-wave lithotripsy, with mixed results overall (Iregui-Parra 2025).
No clinical trials of rosemary or basil for kidney outcomes were identified. No studies in CKD stages 4 to 5, dialysis or transplant were identified.
Cautions in kidney disease
Herbal content is not standardized or verified for a food supplement; extract strength and contaminants are unknown.
Not studied in advanced CKD or dialysis; potassium and other mineral content is not declared.
Should not delay evaluation of an obstructing stone, infection or a 24-hour urine work-up and proven prevention (fluids, dietary changes, thiazide or citrate where indicated).
Bottom line
Weak, small-trial evidence for stone prevention from one of its three herbs and none for the product. If a stone former insists, it is unlikely to harm a patient with normal kidney function, but it is not a substitute for a metabolic stone work-up.
Sources
Nishiura, J. L., Campos, A. H., Boim, M. A., Heilberg, I. P., & Schor, N. (2004). Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urological Research, 32(5), 362–366. https://doi.org/10.1007/s00240-004-0432-8
Dhawan, S., & Olweny, E. O. (2020). Phyllanthus niruri (stone breaker) herbal therapy for kidney stones; a systematic review and meta-analysis of clinical efficacy, and Google Trends analysis of public interest. The Canadian Journal of Urology, 27(2), 10162–10166. https://pubmed.ncbi.nlm.nih.gov/32333735/
Iregui-Parra, J., Rojas Ossa, V., Arias Salazar, C. M., López Estupiñán, A. D., Díaz Varela, D., Sinisterra Parra, L. M., Diéguez, L., & Emiliani, E. (2025). Phyllanthus niruri in the management of nephrolithiasis: A systematic review of the literature. Actas Urológicas Españolas (English Edition), 49(6), 501791. https://doi.org/10.1016/j.acuroe.2025.501791
Reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. renalcarematters.com, reviewed
FDA Philippines registration
1 current food-supplement registration under the brand FLAVOS. Registration status changes;
confirm a product's current status on the FDA verification portal using its FR number.
For health professionals. Data come from the FDA Philippines food-product
registration database and may lag behind the official record. A food-supplement registration means the product may be sold as food; it is not an approval of safety or efficacy for any disease. Not a substitute for clinical judgment.